KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Leases (2021 - 2025)

Castle Biosciences' Current Leases history spans 5 years, with the latest figure at $1.4 million for Q3 2025.

  • For Q3 2025, Current Leases fell 16.96% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, down 16.96%, while the annual FY2024 figure was $1.7 million, 46.44% up from the prior year.
  • Current Leases for Q3 2025 was $1.4 million at Castle Biosciences, down from $1.6 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.0 million in Q2 2023 and bottomed at $1.1 million in Q3 2023.
  • The 5-year median for Current Leases is $1.4 million (2025), against an average of $1.4 million.
  • The largest annual shift saw Current Leases skyrocketed 62.35% in 2023 before it crashed 37.64% in 2024.
  • A 5-year view of Current Leases shows it stood at $1.2 million in 2021, then soared by 50.72% to $1.8 million in 2022, then tumbled by 36.02% to $1.1 million in 2023, then soared by 46.44% to $1.7 million in 2024, then dropped by 12.97% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Current Leases are $1.4 million (Q3 2025), $1.6 million (Q2 2025), and $1.4 million (Q1 2025).